Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Carcinoma, Endometrioid 1Advanced Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × RO5126766 × Clear all
NCT03875820 2026-03-10

FRAME

Institute of Cancer Research, United Kingdom

Phase 1 Active not recruiting
87 enrolled
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Endometrioid

NCT03681483 2024-07-10

RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
15 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT00773526 2016-11-02

A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.

Hoffmann-La Roche

Phase 1 Completed
52 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡